Business context and reporting period
This is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2012. The filing describes a development-stage biopharmaceutical company focused on cancer drug candidates, with no approved products and minimal collaboration revenue. The request metadata names Alaunos Therapeutics, but the filing itself identifies the registrant as ZIOPHARM Oncology, Inc.
Financial results and liquidity
Amounts below are in millions of dollars, except per-share data.
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Revenue | $0.2 | $0.2 | $0.6 | $0.467 |
| Research and development expense | $16.215 | $10.667 | $48.464 | $44.433 |
| General and administrative expense | $5.712 | $3.742 | $15.462 | $11.017 |
| Net loss | $17.824 | $0.802 | $65.907 | $50.534 |
| Net loss per share | $0.23 | $0.01 | $0.85 | $0.77 |
| Operating cash used | Not stated quarterly | Not stated quarterly | $57.332 | $25.085 |
At September 30, cash and cash equivalents were $95.333 million, versus $104.713 million at December 31, 2011. Working capital was $80.9 million, down from $92.7 million. Current assets were $102.581 million and current liabilities $21.736 million. Total liabilities were $46.612 million, including $21.528 million of warrant liabilities; the filing does not report conventional borrowings or debt. The company reported no cash interest paid.
Cash fell $9.380 million over the first nine months: $57.332 million used in operations and $1.482 million used in investing, partly offset by $49.434 million in financing. Financing included approximately $49.2 million net proceeds from a January 2012 share offering. Common shares outstanding increased from 69.2 million at year-end 2011 to 79.6 million at September 30, 2012.
Material changes versus the prior comparable period
- Q3 R&D expense rose 52% and nine-month R&D rose 9%; increased clinical, manufacturing, preclinical, and employee costs were partly offset in the nine-month comparison by a $17.5 million noncash Intrexon-related charge recorded in 2011.
- G&A expense increased 53% for Q3 and 40% for nine months, including restructuring costs. The company recorded an approximately $1.3 million restructuring charge after announcing management changes and closing its Germantown, Maryland office.
- Nine-month net loss increased by $15.4 million. Nine-month operating cash use more than doubled, with management citing higher development spending and a related-party prepayment.
- Warrant fair-value changes materially affected reported earnings: a $3.945 million gain in Q3 2012 versus a $13.388 million gain in Q3 2011, and a $2.516 million loss for the first nine months of 2012 versus a $4.423 million gain in 2011. These are noncash valuation items.
- In January 2012 the company issued 10.114 million shares in an offering for net proceeds of about $49.2 million, contributing to shareholder dilution.
Outlook, commentary, risks, contingencies, and unusual items
- Management estimated available cash would fund operations into the second half of 2013, but said additional financing would be needed for longer-term clinical and product-development plans; there were no committed additional funding sources. Future funding could dilute shareholders or require less favorable collaboration, licensing, or debt terms.
- For the next 12 months, management forecast approximately $91.5 million of R&D expense and $22.9 million of G&A expense, and expected R&D expense to rise as clinical programs advance. Forecasts are subject to trial timing, costs, and other uncertainties.
- The company completed enrollment in the Phase 3 PICASSO 3 palifosfamide soft-tissue-sarcoma trial in June 2012 and expected data in Q4 2012, subject to the independent monitoring committee’s review. It initiated the Phase 3 MATISSE small-cell-lung-cancer trial in June 2012.
- After quarter-end, the first patient was dosed in a Phase 2 ZIN-ATI-001 melanoma study on October 24, 2012. The company issued Intrexon 3,636,926 shares on November 7 under the parties’ stock purchase agreement.
- Contractual obligations totaled $34.483 million: $5.840 million in operating leases, $1.650 million in royalty and license fees, and $26.993 million in CRO milestone payments. Milestone timing depends on clinical and enrollment events. The filing reported no material legal matters, no off-balance-sheet arrangements, and effective disclosure controls.
- Key risks include clinical trial failure or delay, regulatory approval uncertainty, reliance on contract manufacturers and CROs, intellectual-property challenges, rising development costs, and inability to raise capital. The company had not generated product revenue or achieved profitability.
Most important facts for investors to verify
- Whether PICASSO 3 produced the anticipated results and whether regulators considered the evidence sufficient for an approval filing.
- Actual cash burn and remaining runway compared with management’s second-half-2013 estimate and expense forecast.
- Progress, safety findings, enrollment, and costs for MATISSE and the synthetic-biology clinical programs.
- Further financing needs, potential dilution, and the effect of the additional Intrexon share issuance.
- The assumptions and future earnings impact of the $21.528 million warrant liability and other noncash fair-value changes.